



Therapy Acceleration Program[®]

Portfolio Assets in Company Sponsored Trials
Blood Cancer Development



Therapy	Target/Modality	Indications	Preclinical	Phase 1	Phase 2	Phase 2 Reg / Phase 3
Magrolimab + Azacitidine	Anti-CD47 antibody	MDS				
Magrolimab + Rituximab	Anti-CD47 antibody	DLBCL				
AFM13	CD30/CD16A bispecific engager	PTCL				
CPI-0610 +/- Ruxolitinib	BET small molecule	MPN				
Cobomarsen	miR-155 small molecule	CTCL				
Duvelisib + Romidepsin	PI3Kδ/γ small molecule	PTCL				
K-NK002	NK Cell Therapy	AML/MDS				
Cusatuzumab + Azacitidine	Anti-CD70 antibody	MDS				
Cusatuzumab + Ven + Aza	Anti-CD70 antibody	AML				
STRO-001	Anti-CD74 antibody	MM/DLBCL/ MCL/FL				
Mavorixafor + Ibrutinib	CXCR4 small molecule	Waldenström macroglobulinemia				
SEL120	CDK8/19 small molecule	AML/MDS				
PVX-410 + ACY-241 +/- Len	vaccine	Smoldering myeloma				
KO-539	Menin small molecule	MLL leukemia				
NEXI-001	T Cell Therapy	AML				
NEXI-002	T Cell Therapy	Multiple myeloma				
BTX-A51	CK1-α/CDK7/CDK9 small molecule	AML/MDS				
PROTACs	IRAK4 & STAT3 small molecules	Lymphoma				

Updated October 2020